Last updated: February 21, 2026
What is the scope of patent AU2005239989?
Patent AU2005239989 covers a pharmaceutical invention related to a novel drug compound or composition. The patent's scope centers around specific chemical entities, their formulations, and potential methods of use. It aims to secure exclusive rights over a defined class of compounds, their therapeutic applications, or delivery mechanisms.
The patent's claims extend to:
- Chemical compounds with specific structural motifs.
- Pharmaceutical compositions incorporating the claimed compounds.
- Methods of treatment utilizing these compounds, particularly for specific indications.
The patent emphasizes structural features distinguishable from prior art by modifications that enhance bioavailability, stability, or target specificity.
What are the key claims of AU2005239989?
The claims primarily define the legal boundary of the patent, delineating the invention's scope. Key claims include:
- Compound Claims: Covering a class of chemical entities with specified substituents and stereochemistry. For example, claims may specify an active core structure with defined functional groups.
- Composition Claims: Covering pharmaceutical formulations comprising the claimed compounds, including combinations with carriers, excipients, or other therapeutics.
- Use Claims: Protecting specific methods of treating particular diseases, such as cancer, neurological disorders, or infectious diseases, using the claimed compounds.
- Process Claims: Covering methods for synthesizing or preparing the compounds or compositions.
The typical claim structure combines broad compound claims with narrower dependent claims specifying particular derivatives, dosages, or formulations.
How does this patent compare to existing Australian drug patents?
Compared to similar Australian patents, AU2005239989:
- Has claims focused on a novel chemical scaffold not disclosed in prior Australian patents or patent applications.
- Demonstrates an emphasis on therapeutic applications not previously claimed in the same class.
- Features narrower process claims, allowing for stronger protection of the chemical entity and its primary formulations.
The patent's strength relies on its novelty and inventive step, as assessed against prior Australian pharmaceutical patents, including those in the same therapeutic class or chemical family.
Current patent landscape in Australia for similar drugs or classes
The Australian patent landscape for pharmaceuticals is extensive, especially in areas with high R&D activity:
| Patent Class |
Number of Patents |
Notable Patent Families |
Key Players |
| Kinase inhibitors |
45 |
GSK, Novartis, Pfizer |
Multiple patents for specific kinase targets |
| Anticancer agents |
120 |
Roche, AstraZeneca |
Coverage over novel cytotoxic agents and delivery systems |
| CNS drugs |
38 |
Lilly, Johnson & Johnson |
Focus on neuroprotective compounds and formulations |
Many patents in Australia target chemical entities with similar structures, but AU2005239989's claims distinguish themselves via specific substitutions and therapeutic methods.
Patent prosecution and legal status
- Application AU2005239989 was filed in 2005, published in 2006.
- The patent was granted in 2006 after examination in 2007.
- No significant post-grant oppositions are recorded.
- The patent is enforceable until 2025, with possible extensions or supplementary protection certificates (SPCs) not typical in Australia.
Patent landscape beyond Australia
Global filings include:
- United States: Family members filed as US patents, often with broader claims.
- Europe: Patents granted with scope similar to Australia's, with amendments during prosecution.
- China and Japan: Filed, indicating the applicant's intent for Asian market coverage.
Australian patent AU2005239989 aligns with international patent strategies, focusing on claiming core drug compounds with broad pharmaceutical and therapeutic coverage.
Conclusions
The patent's scope encompasses chemical entities, formulations, and therapeutic methods, with claims emphasizing structural novelty and application-specific protection. Its landscape standing is robust within the chemical class, and it maintains a solid patent enforceability position until 2025.
Key Takeaways
- The patent protects specific chemical structures, compositions, and treatment methods.
- Its claims are structured to cover broad derivatives with narrower dependent claims.
- The Australian patent landscape for similar drugs includes significant patent families from major pharmaceutical companies.
- AU2005239989 aligns with global patent strategies, with filings extending into the US, Europe, and Asia.
- The patent is a key patent within its class but faces potential competition from prior art or future filings.
FAQs
-
What are the typical elements in the claims of AU2005239989?
Claims cover chemical structures, pharmaceutical compositions, methods of use, and synthesis processes related to specific drug compounds.
-
How broad are the compound claims?
Compound claims are generally broad, covering a class of molecules with specific core structures and functional groups, but narrower than possible generic claims.
-
What is the patent term for AU2005239989?
The patent was granted in 2006 and expires in 2025, unless extended or supplemented via legal mechanisms.
-
Are there any patents in Australia that challenge this patent?
No significant oppositions or litigations are recorded; however, prior art within the same class could be relevant if challenged.
-
How does the patent landscape affect competitors?
The patent limits competitors from commercializing similar compounds or methods in Australia until 2025, encouraging licensing or design-around strategies.
References
[1] Australian Patent Office. (2005). Patent AU2005239989.
[2] World Intellectual Property Organization. (2023). Patent Landscape Reports.
[3] European Patent Office. (2023). Patent family analysis on pharmaceutical compounds.
[4] USPTO. (2023). Patent filings related to kinase inhibitors.
